ARQT

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Gilbert CisnerosDemocrat $8.0k BuyMar 3, 2026 $1k-$15k -- --

Insider Trades

Name	Value	Action	Price	Current Price
Burnett PatrickSee Remarks $4.7k222 shares SellMay 11, 2026 $21.05 --
Vairavan LathaSVP Chief Financial Officer $9.2k435 shares SellMay 11, 2026 $21.05 --
Matsuda MasaruSee Remarks $172k7.4k shares SellMay 4, 2026 $23.27 --
Watanabe ToddDirector, Officer: See Remarks $75k3.2k shares SellMay 4, 2026 $23.61 --
Vairavan LathaSVP Chief Financial Officer $32k1.3k shares SellMay 4, 2026 $23.61 --
Burnett PatrickSee Remarks $16k684 shares SellMay 4, 2026 $23.61 --

News

globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5

globenewswire.comNew Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatologyglobenewswire.comJun 3

globenewswire.comArcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comMay 26

seekingalpha.comArcutis Biotherapeutics: The Dermatology Platform Is Starting To Compoundseekingalpha.comMay 15

globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 8

Trade ARQT

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

CEO: Todd Franklin Watanabe
IPO Date: Jan 31, 2020

Market Data

Open: $21.85
High: $22.19
Low: $21.05
Volume: 1.2M
52W High: $31.77
52W Low: $12.72

Valuation

Market Cap: $2.7B
Enterprise Value: $2.6B

Financials

Free Cash Flow: $-6.3M
Revenue: $376M
Net Income: $-16M
Cash: $43M
Debt: $6.3M

Events

EarningsAug 5

EPS est. 0.04